Citation: HUANG Chu-Sheng, TU Wen-Tong, LUO Min, SHI Jian-Cheng. Molecular Docking and Design of Novel Heterodimers of Donepezil and Huperzine Fragments as Acetylcholinesterase Inhibitors[J]. Chinese Journal of Structural Chemistry, ;2016, 35(6): 839-848. doi: 10.14102/j.cnki.0254-5861.2011-0733 shu

Molecular Docking and Design of Novel Heterodimers of Donepezil and Huperzine Fragments as Acetylcholinesterase Inhibitors

1.
College of Chemistry and material Sciences, Guangxi Teachers Education University, Nanning 530001, China

Corresponding author: SHI Jian-Cheng,
Received Date: 25 March 2015
Available Online: 12 April 2016
Fund Project:

To provide hints for the design of new acetylcholinesterase (AChE) inhibitors with higher potency and specificity, the binding modes of novel heterodimers comprised of donepezil and huperzine A fragments with AChE were explored by employing the docking simulations. The results show that the binding mode of S-17b (the most potent inhibitor in Ref. 2, i.e., Bioorg. Med. Chem. 2013, 21, 676-683) is clearly different from that of donepezil, while the binding modes of other heterodimers in Ref. 2 are the same as that of donepezil. In addition, based on the binding mode and structure modification of S-17b, two novel inhibitors (S-17b1 and S-17bb1) with much higher inhibitory potency than S-17b were obtained. Our design strategy was to replace the hupyridone moiety of S-17b with the bulky group, and to replace the dimethoxyindanone moiety of S-17b with more hydrophobic and bulky group with a highly positive charge, which would result in generating potent and selective AChE inhibitors.
- molecular docking,
- acetylcholinesterase,
- Alzheimer's disease
1. [1]
  (1) An, P.; Singh, B.; Singh, N. A review on coumarins as acetylcholinesterase inhibitors for zheimer's disease. Bioorganic & Medicinal Chemistry 2012, 20, 1175–1180.
2. [2]
  (2) Hu, Y. Q.; Zhang, J.; Chandrashankra, O.; Ip, F. C. F.; Ip, N. Y. Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 2013, 21, 676–683.
3. [3]
  (3) Shen, L. L.; Liu, G. X.; Tang, Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta Pharmacol Sin. 2007, 28, 2053–2063.
4. [4]
  (4) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew. Chem., Int. Ed. 2000, 39, 1775–1777.
5. [5]
  (5) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2335–2338.
6. [6]
  (6) Alonso, D.; Dorronsoro, I.; Rubio, L.; Muñz, P.; García-Palomero, E.; Del Monte, M.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Castro, A.; Medina, M.; Martínez, A. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem. 2005, 13, 6588–6597.
7. [7]
  (7) Shao, D.; Zou, C.; Luo, C.; Tang, X.; Li, Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Bioorg. Med. Chem. Lett. 2004, 14, 4639–4642.
8. [8]
  (8) Camps, P.; Formosa, X.; Galdeano, C.; Gomez, T.; Munoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M. V.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F. J. J. Med. Chem. 2008, 51, 3588–3598.
9. [9]
  (9) Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem. 2010, 17, 1825–1838.
10. [10]
  (10) Viayna, E.; Gomez, T.; Galdeano, C.; Ramirez, L.; Ratia, M.; Badia, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Camps, P.; Munoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-alzheimer drug candidates. Chem. Med. Chem. 2010, 5, 1855–1870.
11. [11]
  (11) Monte-Millan, M.; Garcia-Palomero, E.; Valenzuela, R.; Usan, P.; de Austria, C.; Munoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martinez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. J. Mol. Neurosci. 2006, 30, 85–88.
12. [12]
  (12) Chitranshi, N.; Gupta, S.; Tripathi, P. K.; Seth, P. K. New molecular scaffolds for the design of Alzheimer's acetylcholinesterase inhibitors identified using ligand and receptor-based virtual screening. Med. Chem. Res. 2013, 22, 2328–2345.
13. [13]
  (13) Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078–1082.
14. [14]
  (14) Drews, J. Drug discovery: a historical perspective. Science 2000, 287, 1960–1964.
15. [15]
  (15) Deb, P. K.; Sharma, A.; Piplani, P.; Akkinepally, R. R. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors. Mol. Divers. 2012, 16, 803–823.
16. [16]
  (16) Steiner, S.; Anderson, N. L. Pharmaceutical proteomics. AnnNY Acad Sci. 2000, 919, 48–51.
17. [17]
  (17) Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, A. M.; Foley, M.; Haystead, T. A. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 2002, 62, 1364–1372.
18. [18]
  (18) Bruneau, J. M.; Maillet, J.; Tagat, E. Drug induced proteome changes in Candida albicans: comparison of the effect of beta (1, 3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics 2003, 3, 325–336.
19. [19]
  (19) Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. J. Structures of human acetylcholinesterasein complex with pharmacologically important ligands. J. Med. Chem. 2012, 55, 10282–10286.
20. [20]
  (20) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Mont Gomery, Jr. J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, Revision C. 02, Gaussian, Inc., Wallingford CT 2004.
21. [21]
  (21) Kryger, G.; Silman, I.; Sussman, J. L. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J. Physiol. Paris 1998, 92, 191–194.
22. [22]
  (22) Nachon, F.; Carletti, E.; Ronco, C.; Trovaslet, M.; Nicolet, Y.; Jean, L.; Renard, P. Y. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl-and butyryl-cholinesterase. Biochem. J. 2013, 453, 393–399.
23. [23]
  (23) Carletti, E.; Colletier, J. P.; Dupeux, F.; Trovaslet, M.; Masson, P.; Nachon, F. Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation. J. Med. Chem. 2010, 53, 4002–4008.
24. [24]
  (24) Taylor, J. L.; Mayer, R. H.; Hime, C. M. Conformers of acetylcholinesterase: a mechanism of allosteric control. Mol. Pharmacol. 1994, 45, 74–83.
25. [25]
  (25) Pang, Y. P.; Quiram, P.; Jalacie, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646–23649.
26. [26]
  (26) Bolognes, M. L.; Banzi, R.; Bartolini, M.; Cavall, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem. 2007, 50, 4882–4897.
27. [27]
  (27) Bolognesi, M. L.; Bartolini, M.; Mancin, F.; Chiriano, G.; Ceccarini, L.; Rosini, M.; Milelli, A.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities. Chem. Med. Chem. 2010, 5, 1215–1220.
28. [28]
  (28) Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297–307.
29. [29]
  (29) Volkov, A.; King, H. F.; Coppens, P.; Farrugia, L. On the calculation of the electrostatic potential, electric field and electric field gradient from the aspherical pseudoatom model. Acta Crystallogr. A 2006, 62, 400–408.
30. [30]
  (30) Luger, P.; Hübschle, C. B. MolIso–a program for colour-mapped iso-surfaces. J. Appl. Crystallogr. 2006, 39, 901–904.
31. [31]
  (31) Luger, P.; Weber, M.; Dittrich, B. Electron density study of the anti-Alzheimer's disease drug donepezil from conventionalx-ray data and invariom database application. Future Med. Chem. 2012, 4, 1399–1407.
32. [32]
  (32) Chen, J. W.; Luo, Y. L.; Hwang, M. J.; Peng, F. C.; Ling, K. H. A tremorgenic mycotoxin that inhibits acetylcholinesterase with a noncovalent yet irreversible binding mechanism. J. Biol. Chem. 1999, 274, 34916–34923.
33. [33]
  (33) Ling, K. H.; Chiou, C. M.; Tseng, Y. L. Biotransformation of territrems by S9 fraction from rat liver. Drug Metab. Dispos. 1991, 19, 587–595.
34. [34]
  (34) Wu, W. J.; Lai, R.; Zheng, K. C.; Yun, F. C. Quantitative structure-activity relationship of indolo[1,2-b] quinazoline derivatives with antitumor activity. Acta Phys.-Chim. Sin. 2005, 21, 28–32.
35. [35]
  (35) Wang, X. W.; Jiang, G.; Du, J. G. Structures, infrared spectra and reactivities of (+)-catechin metal complexes. Acta Phys. Chim. Sin. 2011, 27, 309–314.
36. [36]
  (36) Feng, C. J. Theoretical studies on quantitative structure-activity relationship and structural modification for 3-substituted sulfur-5-(2-hydroxyphenyl)-4H-1,2,4-triazole compounds. Acta Chimica Sinica 2012, 4, 512–518.
37. [37]
  (37) Zhang, J.; Shen, P.; Lu, T.; Yu, D. N.; Li, H.; Yang, G. Z. Theoretical studies on quantitative structure-activity relationship and structural modification for the inhibition of MMP-9 by flavonoids. Acta Chimica Sinica 2011, 4, 383–392.
38. [38]
  (38) Aihara, J. I. Weighted HOMO LUMO energy separation as an index of kinetic stability for fullerenes. Theor. Chem. Acc. 1999, 102, 134-138.
39. [39]
  (39) Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics. Modell. 2002, 20, 281–295.
1. [1]
  Yong Jiao , Pin Yang . Molecular dynamics studies of the inhibitory mechanism of copper(Ⅱ) on aggregation of amyloid β-peptide. Chinese Chemical Letters, 2007, 18(3): 357-360. doi: 10.1016/j.cclet.2006.12.028
2. [2]
  Huihui Zeng , Yujie Qi , Zheyu Zhang , Chuntai Liu , Weijun Peng , Yi Zhang . Nanomaterials toward the treatment of Alzheimer's disease: Recent advances and future trends. Chinese Chemical Letters, 2021, 32(6): 1857-1868. doi: 10.1016/j.cclet.2021.01.014
3. [3]
  Yefei Jiang , Zhiyong Zeng , Jianhua Yao , Ying Guan , Peipei Jia , Xiaoli Zhao , Lin Xu . Treatment of Alzheimer's disease with small-molecule photosensitizers. Chinese Chemical Letters, 2023, 34(5): 107966-1-107966-11. doi: 10.1016/j.cclet.2022.107966
4. [4]
  Jia-Kuo Liu , Wei Gu , Xiao-Rui Cheng , Jun-Ping Cheng , Ai-Hua Nie , Wen-Xia Zhou . Design and synthesis of 3'-(prop-2-yn-1-yloxy)-biphenyl substituted cyclic acylguanidine compounds as BACE1 inhibitors. Chinese Chemical Letters, 2016, 27(6): 961-963. doi: 10.1016/j.cclet.2016.02.006
5. [5]
  Dingchang Liu , Dongjie Fu , Lianbing Zhang , Leming Sun . Detection of amyloid-beta by Fmoc-KLVFF self-assembled fluorescent nanoparticles for Alzheimer's disease diagnosis. Chinese Chemical Letters, 2021, 32(3): 1066-1070. doi: 10.1016/j.cclet.2020.09.009
6. [6]
  Leming Sun , Yang Lei , Yuerong Wang , Dingchang Liu . Blood-based Alzheimer's disease diagnosis using fluorescent peptide nanoparticle arrays. Chinese Chemical Letters, 2022, 33(4): 1946-1950. doi: 10.1016/j.cclet.2021.10.071
7. [7]
  Jian Guo WANG , Yong Jun XIAO , Yong Hong LI , Xing Hai LIU , Zheng Ming LI . Design, Synthesis and Biological Activity of Substituted-N-[4-(substituted-phenylsulfamoyl)phenyl]benzamide as Potential AHAS Inhibitors. Chinese Chemical Letters, 2006, 17(12): 1555-1558.
8. [8]
  Jia-Kuo Liu , Wei Gu , Xiao-Rui Cheng , Jun-Ping Cheng , Wen-Xia Zhou , Ai-Hua Nie . Design and synthesis of cyclic acylguanidines as BACE1 inhibitors. Chinese Chemical Letters, 2015, 26(10): 1327-1330. doi: 10.1016/j.cclet.2015.07.020
9. [9]
  Zhen LIANG , Wen-Li YAN , Hong-Mei LI , Ying LI , Rong ZHANG . Studies on the Molecular Mechanism between HDAC8 and Inhibitory in Different Bioactivities by Molecular Docking and MD Simulations. Chinese Journal of Structural Chemistry, 2021, 40(10): 1298-1308. doi: 10.14102/j.cnki.0254–5861.2011–3126
10. [10]
  Hong-Mei GUO , Na YU , Le FU , Guang-Ping LI , Mao SHU , Zhi-Hua LIN . Discovery of Benzimidazole Derivatives as Novel Aldosterone Synthase Inhibitors: QSAR, Docking Studies, and Molecular Dynamics Simulation. Chinese Journal of Structural Chemistry, 2022, 41(3): 2203193-2203210. doi: 10.14102/j.cnki.0254-5861.2011-3321
11. [11]
  Jian-Cheng SHI , Xiao-Qian HUANG , Min LUO , Chu-Sheng HUANG . Identification of Novel and Potent Curcuminoids Inhibitors of Tubulin with Anticancer Activities by 3D-QSAR and Molecular Docking. Chinese Journal of Structural Chemistry, 2020, 39(6): 1157-1166. doi: 10.14102/j.cnki.0254-5861.2011-2545
12. [12]
  Xiang-Cong WANG , Mao-Cheng YANG , Mo-Xuan ZHANG , Yin-Jie HU , Zhong-Hua WANG , Fan-Hong WU . 3D-QSAR, Molecular Docking and Molecular Dynamics Simulations of 3-Phenylsulfonylaminopyridine Derivatives as Novel PI3Kα Inhibitors. Chinese Journal of Structural Chemistry, 2021, 40(12): 1567-1585. doi: 10.14102/j.cnki.0254-5861.2011-3216
13. [13]
  Jian-Bo TONG , Lu-Yang WU , Shan LEI , Tian-Hao WANG , Yang-Min MA . Molecular Modeling Studies of 4-Hydroxyamino α-Pyranone Carboxamide Analogues as Hepatitis C Virus Inhibitor Using 3D-QSAR and Molecular Docking. Chinese Journal of Structural Chemistry, 2020, 39(6): 1135-1145. doi: 10.14102/j.cnki.0254-5861.2011-2539
14. [14]
  Hong-Mei GUO , Le FU , Guang-Ping LI , Mao SHU , Zhi-Hua LIN . Discovery of Novel Acetaldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Chinese Journal of Structural Chemistry, 2021, 40(5): 549-564. doi: 10.14102/j.cnki.0254–5861.2011–2982
15. [15]
  Xiao-Zhong CHEN , Guang-Ping LI , Yan SHEN , Yong HU , Juan WANG , Yuan-Qiang WANG , Zhi-Hua LIN . Docking and 3D-QSAR Studies on the Imidazo[1, 5-c]pyrimidine Derivative as EED Inhibitors. Chinese Journal of Structural Chemistry, 2021, 40(6): 689-702. doi: 10.14102/j.cnki.0254–5861.2011–2994
16. [16]
  Jian-Bo TONG , Tian-Hao WANG , Ying-Ji WU , Yi FENG . QSAR and Docking Studies of Thiazolidine-4-carboxylic Acid Derivatives as Neuraminidase Inhibitors. Chinese Journal of Structural Chemistry, 2020, 39(4): 651-661. doi: 10.14102/j.cnki.0254-5861.2011-2508
17. [17]
  Di LI . Anti-lung Cancer Activity and Docking Study of Two Novel Isochroman Derivatives. Chinese Journal of Structural Chemistry, 2020, 39(5): 901-907. doi: 10.14102/j.cnki.0254–5861.2011–2542
18. [18]
  Wen-Li YAN , Zhen LIANG , Xing-Lian YU , Rong ZHANG . Mechanism Study of Aliskiren and Its Analogues by Molecular Dynamic Simulation. Chinese Journal of Structural Chemistry, 2022, 41(3): 2203178-2203185. doi: 10.14102/j.cnki.0254-5861.2011-3308
19. [19]
  Jian-Bo TONG , Xue-Chun XIAO , Ding LUO , Hai-Yin XU , Jie WANG . QSAR Study and Molecular Design of Isoquinolone Derivative JNK1 Inhibitors. Chinese Journal of Structural Chemistry, 2021, 40(12): 1586-1594. doi: 10.14102/j.cnki.0254-5861.2011-3227
20. [20]
  Qing-Xiu HE , Guang-Ping LI , Hai-Qiong GUO , Yu-Xuan WANG , Han CHU , Yong HU , Yan SHEN , Zhi-Hua LIN , Yuan-Qiang WANG . Discovery of Potential SARS-CoV-2 M Protease Inhibitors by Virtual Screening, Molecular Dynamics, and Binding Free Energy Analyses. Chinese Journal of Structural Chemistry, 2021, 40(4): 431-442. doi: 10.14102/j.cnki.0254-5861.2011-2966

Get Citation

PDF

XML

Metrics

PDF Downloads(4)
Abstract views(2691)
HTML views(134)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142